RT Journal Article
SR Electronic
T1 Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.12.21261921
DO 10.1101/2021.08.12.21261921
A1 Pradenas, Edwards
A1 Trinité, Benjamin
A1 Urrea, Víctor
A1 Marfil, Silvia
A1 Tarrés-Freixas, Ferran
A1 Ortiz, Raquel
A1 Rovirosa, Carla
A1 Rodon, Jordi
A1 Vergara-Alert, Júlia
A1 Segalés, Joaquim
A1 Guallar, Victor
A1 Valencia, Alfonso
A1 Izquierdo-Useros, Nuria
A1 Noguera-Julian, Marc
A1 Carrillo, Jorge
A1 Paredes, Roger
A1 Mateu, Lourdes
A1 Chamorro, Anna
A1 Toledo, Ruth
A1 Massanella, Marta
A1 Clotet, Bonaventura
A1 Blanco, Julià
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.12.21261921.abstract
AB Background Understanding the determinants of long-term immune responses to SARS-CoV-2 and the concurrent impact of vaccination and emerging variants of concern will guide optimal strategies to achieve global protection against the COVID-19 pandemic.Methods A prospective cohort of 332 COVID-19 patients was followed beyond one year. Plasma neutralizing activity was evaluated using HIV-based reporter pseudoviruses expressing different SARS-CoV-2 spikes and was longitudinally analyzed using mixed-effects models.Findings Long-term neutralizing activity was stable beyond one year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while outpatient responses were dominated by long-lived B cells. In both groups, vaccination boosted responses to natural infection, although viral variants, mainly B.1.351, reduced the efficacy of neutralization. Importantly, despite showing higher neutralization titers, hospitalized patients showed lower cross-neutralization of B.1.351 variant compared to outpatients. Multivariate analysis identified severity of primary infection as the factor that independently determines both the magnitude and the inferior cross-neutralization activity of long-term neutralizing responses.Conclusions Neutralizing response induced by SARS-CoV-2 is heterogeneous in magnitude but stable beyond one year after infection. Vaccination boosts these long-lasting natural neutralizing responses, counteracting the significant resistance to neutralization of new viral variants. Severity of primary infection determines higher magnitude but poorer quality of long-term neutralizing responses.Competing Interest StatementUnrelated to the submitted work, JB and JC are founders and shareholders of AlbaJuna Therapeutics, S.L. BC is founder and shareholder of AlbaJuna Therapeutics, S.L and AELIX Therapeutics, S.L. The other authors do not declare conflict of interest.Funding StatementGrifols, Departament de Salut of the Generalitat de Catalunya, the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya, ANID, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat and Correos.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study KING was approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol (HUGTiP, PI-20-122 and PI-20-217) and was further amended to include vaccinated individuals. All participants provided written informed consent before inclusion.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Julià Blanco (jblanco{at}irsicaixa.es). This study did not generate any unique datasets or code.